Notice of General Meeting/Proxy Form
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
16 November 2026
Dear Shareholder,
Neurizon Therapeutics Limited – General Meeting of Shareholders – 17 December 2026
Notice is hereby given that the General Meeting of Shareholders of Neurizon Therapeutics Limited
(“Company”) will be held as a virtual only meeting at 9.00am (AEDT) on Thursday, 17 December 2026
accessible virtually through an online meeting platform (“General Meeting”, “GM” or “Meeting”).
The Company will not be dispatching physical copies of Meeting documents and notices, including the
Notice of Meeting for the GM, unless you request a physical copy to be posted to you.
The Notice of Meeting and accompanying explanatory statement (“Meeting Materials”) are being made
available to shareholders electronically. This means that:
- You can access the Meeting Materials online at the Company’s website https://www.neurizon.com/
or at the Company’s share registry’s website https://portal.automic.com.au/investor/home.
- A complete copy of the Meeting Materials has been posted to the Company’s ASX Market
announcements page at www.asx.com.au under the Company’s ASX code “NUZ”.
- If you have provided an email address and have elected to receive electronic communications from
the Company, you will receive an email to your nominated email address with a link to an electronic
copy of the Meeting Materials and the voting instruction form.
Shareholders can still elect to receive some or all of their communications in physical or electronic form,
or elect not to receive certain documents such as annual reports. To review your communications
preferences or sign up to receive your shareholder communications via email, please update your details
at https://investor.automic.com.au/. If you have not yet registered, you will need your shareholder
information including SRN/HIN details.
If you are unable to access the Meeting Materials online please contact our share registry Automic at
meetings@automicgroup.com.au or by phone on 1300 288 664 (within Australia) or +61 2 9698 5414
(outside Australia) between 9:00am and 5:00pm (AEDT) Monday to Friday, to obtain a copy.
Details of how to register to attend the Meeting online are contained in the Meeting Materials.
Shareholders are encouraged to submit their proxies as soon as possible in advance of the Meeting, even
if they are planning to attend the Meeting online.
Yours sincerely,
Stefan Ross
Company Secretary
Neurizon Therapeutics Limited
NEURIZON THERAPEUTICS LIMITED
ABN 35 094 006 023
Notice of General Meeting
Explanatory Statement and Proxy Form
Date of Meeting:
Thursday, 17 December 2026
Time of Meeting:
9.00am (AEDT)
Place of Meeting:
[Gilbert + Tobin
Level 25, 101 Collins Street
Melbourne VIC 3000]
Online access:
[I
This Notice of General Meeting and Explanatory Statement should be read in its entirety.
If Shareholders are in doubt as to how they should vote, they should seek advice from their accountant,
solicitor, or other professional advisor without delay.
NEURIZON THERAPEUTICS LIMITED
ABN 35 094 006 023
Registered office: Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000
Notice is hereby given that the General Meeting of Shareholders of Neurizon Therapeutics Limited (Neurizon
or the Company) will be held as a virtual only meeting at 9.00am (AEDT) on Thursday, 17 December 2026
accessible virtually through an online meeting platform (General Meeting, GM or Meeting).
In accordance with the Corporations Act, the Notice of Meeting and accompanying Explanatory Statement (Meeting Materials)
are being made available to Shareholders electronically. This means that:
- You can access the Meeting Materials online at the Company’s website https://investorhub.neurizon.com/ or at the
Company’s share registry’s website https://www.automicgroup.com.au/ by logging in with your Shareholder Reference
Number (SRN) or Holder Identification Number (HIN).
- A complete copy of the Meeting Materials has been posted to the Company’s ASX Market announcements page at
www.asx.com.au under the Company’s ASX code “NUZ”.
- If you have provided an email address and have elected to receive electronic communications from the Company, you will
receive an email to your nominated email address with a link to an electronic copy of the Meeting Materials and the voting
instruction form.
The Company will not be dispatching physical copies of Meeting documents and notices, including the Notice of Meeting for the
GM, unless you request a physical copy to be posted to you.
Shareholders can elect to receive some or all of their communications in physical or electronic form, or elect not to receive certain
documents such as annual reports. To review your communications preferences, or sign up to receive your Shareholder
communications via email, please update your details at https://www.automicgroup.com.au/. If you have not yet registered, you
will need your Shareholder information including SRN/HIN details.
Shareholders are encouraged to submit their proxies as early as possible, and in any event, prior to the cut-off date for proxy
voting, being 9.00am (AEDT) on Tuesday, 15 December 2026. To lodge your proxy, please follow the directions on your
personalised Proxy Form.
The Company will conduct a poll on each resolution presented at the Meeting. The Company is happy to accept and answer
questions submitted prior to the Meeting by email to stefan.ross@vistra.com. The Company will address relevant questions during
the Meeting or by written response after the Meeting (subject to the discretion of the Company not to respond to unreasonable
and/or offensive questions).
How do I participate in the Meeting?
Shareholders must use the Automic Meeting Platform to attend and participate in the Meeting.
To participate in the Meeting, you can login by entering the following https://portal.automic.com.au/investor/home on your
computer, tablet or smartphone.
Online registration will open 30 minutes before the Meeting.
To make the registration process quicker, please have your SRN/HIN and registered postcode or country code ready.
Proxyholders will need to contact Automic prior to the Meeting to obtain their login details.
To participate in the Meeting online follow the instructions below.
1. Open your internet browser and go to investor.automic.com.au
2. Login with your username and password or click “Register” if you haven’t already created an account.
Shareholders are encouraged to create an account prior to the start of the Meeting to ensure there is no
delay in attending the virtual Meeting.
3. After logging in, a banner will display at the bottom of your screen to indicate that the Meeting is open for
registration, click on “Register” when this appears. Alternatively, click on “Meetings” on the left-hand menu
bar to access registration.
4. Click on “Register” and follow the steps.
5. Click on the URL to join the webcast where you can view and listen to the virtual Meeting. Note that the
webcast will open in a separate window.
You can view the Meeting live, ask questions verbally or via a live Q&A facility and cast votes at the appropriate times while the
Meeting is in progress.
Voting virtually at the Meeting
Shareholders are encouraged to vote ahead of the Meeting by completing and returning the enclosed Proxy Form.
Once the Chair of the Meeting has declared the poll open for voting click on “Refresh” within the platform to be taken to the
voting screen.
Select your voting direction and click “Confirm” to submit your vote. Note that you cannot amend your vote after it has been
submitted.
For further information on the live voting process please see the Registration and Voting Guide at
https://www.automicgroup.com.au/virtual-agms/.
Voting by proxy
To vote by proxy, please use one of the following methods:
Online Lodge your proxy form online at https://portal.automic.com.au/investor/home by following the
instructions: Login to the Automic website using the holding details as shown on the Proxy Form.
Click on “View Meetings” – “Vote”. To use the online lodgement facility, Shareholders will need their
holder number (Shareholder Reference Number (SRN) or Holder Identification Number (HIN)) as
shown on the front of the Proxy Form.
For further information on the online proxy lodgement process please see the Online Proxy
Lodgement Guide at https://www.automicgroup.com.au/virtual-agms/.
By post Automic, GPO Box 5193, Sydney NSW 2001
By hand Automic, Level 5, 126 Phillip Street, Sydney NSW 2000
By email Completing the enclosed Proxy Form and emailing it to: meetings@automicgroup.com.au
Chair’s Letter
16 November 2026
Dear Shareholder,
It’s my pleasure to invite you to the General Meeting of Neurizon Therapeutics Limited, which will take place on
Thursday, 17 December 2026.
We encourage you to participate in the GM, either online or by proxy, and to vote on the resolutions.
Shareholders are encouraged to submit their proxies as early as possible, and in any event, prior to the cut-off date
for proxy voting, being 9.00am (AEDT) on Tuesday, 15 December 2026. To lodge your proxy, please follow the
directions on your personalised Proxy Form.
You may submit your vote online at https://investor.automic.com.au/ using the details provided on the Proxy Form.
If you have any questions regarding the resolutions or the GM process, please do not hesitate to contact our
Company Secretary, Stefan Ross, at +61 3 9692 7222.
Thank you for your continued support and we look forward to your participation at the GM.
Yours sincerely,
Sergio Duchini
Chair
Neurizon Therapeutics Limited
NEURIZON THERAPEUTICS LIMITED
ABN 35 094 006 023
Registered office: Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000
AGENDA
The Explanatory Statement and Proxy Form which accompany and form part of this Notice include defined terms
and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement
and the Proxy Form in their entirety.
ORDINARY BUSINESS
Resolution 1: Ratification of prior issue of 61,764,704 Shares
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 7.4, and for all other purposes, Shareholders approve, ratify and confirm the
prior agreement to allot and issue, and the subsequent allotment and issue, of 61,764,704 Shares at an issue price
of $0.068 (6.8 cents) per Share in relation to the Placement to sophisticated and/or professional investors, as
described in the Explanatory Statement which accompanies and forms part of this Notice.”
Resolution 2: Approval to issue Shares to Mr Sergio Duchini (and/or his nominee(s) or associate(s)) in
relation to the Placement
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.11, and for all other purposes, approval be given to issue 735,294 Shares
at an issue price of $0.068 (6.8 cents) per Share to Mr Sergio Duchini (Non-Executive Chair of the Company), and/or
his nominee(s) or associate(s), as part of the Placement announcement on 2 November 2026 on the terms and
conditions set out in the Explanatory Statement which accompanies and forms part of this Notice.”
Resolution 3: Approval to issue Shares to Mr Marcus Hughes (and/or his nominee(s) or associate(s)) in
relation to the Placement
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.11, and for all other purposes, approval be given to issue 735,294 Shares
at an issue price of $0.068 (6.8 cents) per Share to Mr Marcus Hughes (Non-Executive Director of the Company),
and/or his nominee(s) or associate(s), as part of the Placement announcement on 2 November 2026 on the terms
and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice.”
Resolution 4: Approval to issue 61,764,704 Options to placees who are Unrelated Investors
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 7.1, and for all other purposes, approval be given to issue 61,764,704 Options
with an exercise price of $0.12 (12 cents) per Option and an expiry date of 18 months from the date of issue to
unrelated sophisticated and/or professional investors on the terms and conditions set out in the Explanatory
Statement which accompanies and forms part of this Notice (including Schedule 1 of the Explanatory Statement).”
Resolution 5: Approval to issue Options to Mr Sergio Duchini (and/or his nominee(s) or associate(s))
(conditional item)
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“Subject to and conditional on the passing of resolutions 2 and 4, that, for the purposes of Listing Rule 10.11, and for
all other purposes, approval be given to issue 735,294 Options with an exercise price of $0.12 (12 cents) per Option
and an expiry date of 18 months from the date of issue to Mr Sergio Duchini (Non-Executive Chair of the Company),
and/or his nominee(s) or associate(s) on the terms and conditions set out in the Explanatory Statement which
accompanies and forms part of this Notice (including Schedule 1 of the Explanatory Statement).”
Resolution 6: Approval to issue Options to Mr Marcus Hughes (and/or his nominee(s) or associate(s))
(conditional item)
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“Subject to and conditional on the passing of resolutions 3 and 4, that, for the purposes of Listing Rule 10.11, and for
all other purposes, approval be given to issue 735,294 Options with an exercise price of $0.12 (12 cents) per Option
and an expiry date of 18 months from the date of issue to Mr Marcus Hughes (Non-Executive Director of the
Company), and/or his nominee(s) or associate(s) on the terms and conditions set out in the Explanatory Statement
which accompanies and forms part of this Notice (including Schedule 1 of the Explanatory Statement).”
Resolution 7: Approval to issue Options to Eligible Shareholders who participate in the SPP
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 7.1, and for all other purposes, approval be given to issue up to 147,058,824
Options with an exercise price of $0.12 (12 cents) per Option and an expiry date of 18 months from the date of issue
to Eligible Shareholders who, and to the extent, participate in the SPP on the terms and conditions set out in the
Explanatory Statement which accompanies and forms part of this Notice (including Schedule 1 of the Explanatory
Statement).”
By order of the Board
Stefan Ross
Company Secretary
16 November 2026
NOTES:
(1) Entire Notice: The details of the resolutions contained in the Explanatory Statement accompanying this Notice of Meeting should be read
together with, and form part of, this Notice of Meeting.
(2) Record Date: The Company has determined that for the purposes of the General Meeting, Shares will be taken to be held by the persons
who are registered as holding the Shares at 7.00pm (AEDT) on the date 48 hours before the date of the General Meeting. Only those
persons will be entitled to vote at the General Meeting and transfers registered after that time will be disregarded in determining entitlements
to attend and vote at the General Meeting.
(3) Proxies
a. Votes at the General Meeting may be given personally or by proxy, attorney or representative.
b. Each Shareholder has a right to appoint one or two proxies.
c. A proxy need not be a Shareholder of the Company.
d. If a Shareholder is a company it must execute under its common seal or otherwise in accordance with its constitution, or the
Corporations Act.
e. Where a Shareholder is entitled to cast two or more votes, the Shareholder may appoint two proxies and may specify the proportion
or number of votes each proxy is appointed to exercise.
f. If a Shareholder appoints two proxies, and the appointment does not specify the proportion or number of the Shareholder’s votes,
each proxy may exercise half of the votes. If a Shareholder appoints two proxies, neither proxy may vote on a show of hands.
g. A proxy must be signed by the Shareholder or his or her attorney who has not received any notice of revocation of the authority.
Proxies given by corporations must be signed in accordance with the corporation’s constitution and the Corporations Act.
h. To be effective, proxy forms must be received by the Company’s share registry (Automic) no later than 48 hours before the
commencement of the General Meeting, this is no later than 9.00am (AEDT) on Tuesday, 15 December 2026. Any proxy received
after that time will not be valid for the scheduled Meeting. Proxy forms may be lodged:
(1) online by going to https://portal.automic.com.au/investor/home or by scanning the QR code found on the enclosed Proxy Form
with your mobile device;
(2) by post to Automic, GPO Box 5193, Sydney NSW 2001;
(3) by hand to Automic, Level 5, 126 Phillip Street, Sydney NSW 2000; and
(4) by email by completing the Proxy Form and emailing it to: meetings@automicgroup.com.au.
(4) Corporate Representative
Any corporate Shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person
with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company’s representative.
The authority may be sent to the Company and/or registry in advance of the Meeting or provided at the Meeting when registering as a
corporate representative.
(5) How the Chair will vote Undirected Proxies
Subject to the voting exclusions in note 6 of this Notice, the Chair of the Meeting will vote undirected proxies in favour of all of the proposed
resolutions.
(6) Voting Exclusion Statement:
Resolution 1
The Company will disregard any votes cast in favour of resolution 1 by or on behalf of any persons who participated in the issue or any
counterparties to the agreements being approved or any associates of that person or those persons.
However, this does not apply to a vote cast in favour of resolution 1 by:
a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to
the proxy or attorney to vote on the resolution in that way; or
b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a
direction given to the Chair to vote on the resolution as the Chair decides; or
c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met: i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded
from voting, and is not an associate of a person excluded from voting, on the resolution; and ii. the holder votes on the
resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Resolutions 2, 3, 5 and 6
The Company will disregard any votes cast in favour of each of resolutions 2, 3, 5 and 6 (respectively and separately) by or on behalf of:
Mr Sergio Duchini and Mr Marcus Hughes (in respect of each of their standalone resolutions only) or any person(s) who will obtain
a material benefit as a result of the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in
the entity), or
an associate of a person referred to in the preceding paragraph.
However, this does not apply to a vote cast in favour of the relevant resolution by:
a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the
proxy or attorney to vote on the resolution in that way; or
b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction
given to the Chair to vote on the resolution as the Chair decides; or
c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met: i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting,
and is not an associate of a person excluded from voting, on the resolution; and ii. the holder votes on the resolution in accordance
with directions given by the beneficiary to the holder to vote in that way.
Resolutions 4 and 7
The Company will disregard any votes cast in favour of resolutions 4 and 7 (respectively and separately) by or on behalf of any persons
who are expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason
of being a holder of ordinary securities in the entity) or any associates of that person or those persons.
However, this does not apply to a vote cast in favour of the relevant resolution by:
a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to
the proxy or attorney to vote on the resolution in that way; or
b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a
direction given to the Chair to vote on the resolution as the Chair decides; or
c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met: i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded
from voting, and is not an associate of a person excluded from voting, on the resolution; and ii. the holder votes on the
resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
(7) Enquiries
Shareholders are invited to contact the Company Secretary, Stefan Ross on +61 3 9692 7222 if they have any queries in respect of the
matters set out in these documents.
EXPLANATORY STATEMENT
Purpose of Information
This Explanatory Statement (Statement) accompanies and forms part of the Company’s Notice of Meeting for the
General Meeting to be held as a virtual only meeting at 9.00am (AEDT) on Thursday, 17 December 2026 accessible
virtually through an online meeting platform.
The Notice incorporates, and should be read together with, this Statement.
ORDINARY BUSINESS
Background to resolutions
On Monday, 2 November 2026, the Company announced it had received firm commitments to raise $4.3 million via
a placement to institutional, sophisticated and professional investors (Placement). The Placement will result in the
issue of 63,235,292 fully paid ordinary shares (Shares) at an issue price of $0.068 (6.8 cents) per Share, which
includes 1,470,588 Shares to be issued to Directors (and/or their respective nominee(s) or associate(s)), subject to
Shareholder approval (being the subject of resolutions 2 and 3 set out in the Notice of Meeting).
61,764,704 Shares (the subject of resolution 1) were agreed to be issued in a single tranche and were subsequently
issued as such on Monday, 9 November 2026, which was within the Company’s 15% placement capacity under
Listing Rule 7.1.
Directors have committed to participation in the Placement for $100,000 in aggregate subject to Shareholder approval
(the subject of resolutions 2 and 3).
MST Financial Services Pty Ltd (AFSL 500557) (MST) & Morgans Corporate Limited ACN 010 539 607 (Morgans)
acted as joint lead managers and bookrunners in respect of the Placement (together, the Joint Lead Managers).
Participants under the Placement will be entitled to be made an offer by the Company, subject to Shareholder
approval (the subject of resolutions 4 to 6), to apply to receive (for no consideration, with an exercise price of $0.12
(12 cents) per Option and an expiry date of 18 months from the date of issue) 1 Option for every 1 Share issued
under the Placement (rounded down to the nearest whole number) and otherwise subject to the terms and conditions
in Schedule 1.
On Monday, 2 November 2026, the Company also announced that it will offer Eligible Shareholders, being persons
who were registered holders of Shares in Neurizon at 7.00pm (AEDT) on Friday, 30 October 2026, with a registered
address in Australia or New Zealand at that time as shown on the share register, who are not in the United States
and are not acting for the account or benefit of a person in the United States (and who meet certain other eligibility
criteria), the opportunity to participate in a share purchase plan (SPP) and each apply for up to $30,000 worth of
Shares at an issue price of $0.068 (6.8 cents) per Share (being the same issue price as that under the Placement).
The SPP is targeting to raise $2 million. Neurizon may (in its absolute discretion) in a situation where total demand
exceeds $2 million, decide to increase the amount to be raised under the SPP to reduce or eliminate the need for
scale back. Neurizon also reserves the right to scale back applications at its absolute discretion. As the SPP has not
closed, and to accommodate any exercise by Neurizon of its discretion to increase the amount to be raised under
the SPP, resolution 7 assumes the Company receives valid applications from Eligible Shareholders for $10 million
worth of Shares under the SPP (i.e. the Company exercises its discretion to accept the oversubscriptions up to an
amount of $10 million).
Participants under the SPP will be entitled to be made a separate offer by the Company, subject to Shareholder
approval (the subject of resolution 7), to apply to receive (for no consideration) 1 Option for every 1 Share subscribed
for under the SPP (rounded down to the nearest whole number) with an exercise price of $0.12 (12 cents) per Option
and an expiry date of 18 months from the date of issue and otherwise subject to the terms and conditions in Schedule
1.
Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the Options are intended to be
quoted on the ASX and the issue of Options is subject to such quotation. The Options will be issued under a
prospectus to be lodged with ASIC and released to ASX on or around the date of the Notice (Prospectus).
The resolutions contained in the Notice of Meeting are summarised below:
resolution 1 to ratify the prior issue of 61,764,704 Shares under the Placement;
resolutions 2 and 3 to approve the issue of 1,470,588 Shares under the Placement to the Directors of the
Company (and/or their respective nominee(s) or associate(s)); and
resolution 4 to approve the issue of 61,764,704 Options to placees who are Unrelated Investors, resolutions
5 and 6 to approve the issue of 1,470,588 Options to the Directors of the Company (and/or their respective
nominee(s) or associate(s)) and resolution 7 to approve the issue of up to 147,058,824 Options to Eligible
Shareholders who, and to the extent, participate in the SPP.
Funds raised under the Placement and SPP, together with existing cash (following the redemption of all
outstanding convertible notes then held by Obsidian) and anticipated R&D tax incentive refunds, will be applied to:
clinical and pre-clinical activities, including completion of Regimen I of the Phase 2/3 HEALEY ALS
Platform Trial, with topline results anticipated in late Q2 CY2027;
manufacturing, supply-chain readiness and regulatory activities to support the continued clinical
development and preparation for potential commercialisation of NUZ-001;
market engagement and business development activities, including potential strategic partnering
opportunities; and
corporate costs (commercial, finance and governance), working capital and transaction expenses.
Refer to the Company's ASX announcements on Monday, 2 November 2026, together with the SPP offer booklet
and Prospectus lodged on or around the date of the Notice, for further details.
Resolution 1: Ratification of prior issue of 61,764,704 Shares
Background
The Company is seeking Shareholder approval pursuant to Listing Rule 7.4 to approve, ratify and confirm the prior
agreement to allot and issue, and the subsequent allotment and issue, of 61,764,704 Shares in the Company issued
on Monday, 9 November 2026 at an issue price of $0.068 (6.8 cents) per Share, raising $4.2 million, on the terms as
announced on Monday, 2 November 2026.
The Shares were agreed to be issued without Shareholder approval out of the Company’s 15% placement capacity
pursuant to Listing Rule 7.1 and were issued on Monday, 9 November 2026.
Listing Rule requirements
Listing Rule 7.1 allows the Company to issue or agree to issue new securities up to 15% of the existing capital of the
Company in any 12-month period without the prior approval of Shareholders, subject to certain exceptions in Listing
Rule 7.2. The agreement to issue the Shares (and the subsequent issue of the Shares) was within the Company's
available placement capacity under Listing Rule 7.1.
Under Listing Rule 7.4 an issue of, or agreement to issue, securities will be treated as having been made with the
approval of Shareholders for the purposes of Listing Rule 7.1 if the issue or agreement did not breach Listing Rule
7.1 at the time and Shareholders subsequently approve it. The agreement to issue the Shares (and the subsequent
issue of the Shares) was within the Company's Listing Rule 7.1 placement capacity and the Company now seeks
ratification from Shareholders pursuant to Listing Rule 7.4 so as to refresh its capacity to make further issues or
agreements (if required) without Shareholder approval under Listing Rule 7.1.
Resolution 1 seeks Shareholder approval for the purposes of Listing Rule 7.4, and for all other
Share your feedback
Discover